Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

• Informe anual (10-K)

  Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.

  Presentado el 2026-02-25

  Ver documento

• Informe trimestral (10-Q)

  Una actualización del desempeño financiero de los últimos tres meses.

  Presentado el 2026-08-05

  Ver documento

• Informe de hecho relevante (8-K)

  Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.

  Presentado el 2026-09-28

  Ver documento

• 2/26/2026POSITIVE
  13 Analysts Have This To Say About Mirum Pharmaceuticals

  Markets Gazette notes a strong positive consensus among analysts for Mirum Pharmaceuticals (MIRM). Recent evaluations from prominent investment firms such as Raymond James and SVB Leerink have reiterated 'Strong Buy' and 'Outperform' ratings. This persistent optimism, maintained even in recent reviews, signals solid confidence in the pharmaceutical company's future prospects. For investors, the continuation of such high ratings suggests that the market anticipates robust performance and significant growth potential for MIRM stock, despite broader market dynamics. The analysis generally agrees that Mirum Pharmaceuticals possesses strong fundamentals or upcoming catalysts that warrant a favorable portfolio position.

• 2/25/2026NEUTRAL
  Mirum (MIRM) Q4 2025 Earnings Call Transcript

  Mirum Pharmaceuticals (MIRM) held its Q4 2025 earnings call. While the specific details of the transcript are not yet available, this event marks a crucial moment for investors awaiting updates on the company's financial performance. Earnings calls are fundamental for understanding a company's operational health, future projections, and growth strategies. Analysts and shareholders will closely monitor key data points such as revenue, earnings per share, and guidance for the upcoming fiscal year once the transcript is released. The absence of immediate content means the market remains in a holding pattern, awaiting concrete information that could influence the stock's valuation.